Home > Publications Database > Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers. > print

001     272964
005     20241208000026.0
024 7 _ |a 10.1002/alz.14230
|2 doi
024 7 _ |a pmid:39291737
|2 pmid
024 7 _ |a pmc:PMC11567826
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
024 7 _ |a altmetric:167941691
|2 altmetric
037 _ _ |a DZNE-2024-01343
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Liu, Shiwei
|b 0
245 _ _ |a Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers.
260 _ _ |a Hoboken, NJ
|c 2024
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1732007756_11165
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a MicroRNAs (miRNAs) play important roles in gene expression regulation and Alzheimer's disease (AD) pathogenesis.We investigated the association between baseline plasma miRNAs and central AD biomarkers from the Alzheimer's Disease Neuroimaging Initiative (ADNI; N = 803): amyloid, tau, and neurodegeneration (A/T/N). Differentially expressed miRNAs and their targets were identified, followed by pathway enrichment analysis. Machine learning approaches were applied to investigate the role of miRNAs as blood biomarkers.We identified nine, two, and eight miRNAs significantly associated with A/T/N positivity, respectively. We identified 271 genes targeted by amyloid-related miRNAs with estrogen signaling receptor-mediated signaling among the enriched pathways. Additionally, 220 genes targeted by neurodegeneration-related miRNAs showed enrichment in pathways including the insulin growth factor 1 pathway. The classification performance of demographic information for A/T/N positivity was increased up to 9% with the inclusion of miRNAs.Plasma miRNAs were associated with central A/T/N biomarkers, highlighting their potential as blood biomarkers.We performed association analysis of microRNAs (miRNAs) with amyloid/tau/neurodegeneration (A/T/N) biomarker positivity. We identified dysregulated miRNAs for A/T/N biomarker positivity. We identified Alzheimer's disease biomarker-specific/common pathways related to miRNAs. miRNAs improved the classification for A/T/N positivity by up to 9%. Our study highlights the potential of miRNAs as blood biomarkers.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a amyloid
|2 Other
650 _ 7 |a biomarkers
|2 Other
650 _ 7 |a classification
|2 Other
650 _ 7 |a microRNAs
|2 Other
650 _ 7 |a neurodegeneration
|2 Other
650 _ 7 |a plasma
|2 Other
650 _ 7 |a tau
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a MicroRNAs
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: blood
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a MicroRNAs: blood
|2 MeSH
650 _ 2 |a MicroRNAs: genetics
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Machine Learning
|2 MeSH
650 _ 2 |a tau Proteins: blood
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: blood
|2 MeSH
700 1 _ |a Park, Tamina
|b 1
700 1 _ |a Krüger, Dennis M
|0 P:(DE-2719)2812548
|b 2
|u dzne
700 1 _ |a Pena Centeno, Tonatiuh
|0 P:(DE-2719)2811063
|b 3
|u dzne
700 1 _ |a Burkhardt, Susanne
|0 P:(DE-2719)2810773
|b 4
|u dzne
700 1 _ |a Schutz, Anna-Lena
|0 P:(DE-2719)2810585
|b 5
|u dzne
700 1 _ |a Huang, Yen-Ning
|b 6
700 1 _ |a Rosewood, Thea
|b 7
700 1 _ |a Chaudhuri, Soumilee
|b 8
700 1 _ |a Cho, MinYoung
|b 9
700 1 _ |a Risacher, Shannon L
|b 10
700 1 _ |a Wan, Yang
|b 11
700 1 _ |a Shaw, Leslie M
|b 12
700 1 _ |a Sananbenesi, Farahnaz
|0 P:(DE-2719)2811099
|b 13
|u dzne
700 1 _ |a Brodsky, Alexander S
|b 14
700 1 _ |a Lin, Honghuang
|b 15
700 1 _ |a Krunic, Andre
|b 16
700 1 _ |a Blusztajn, Jan Krzysztof
|b 17
700 1 _ |a Saykin, Andrew J
|b 18
700 1 _ |a Delalle, Ivana
|0 0000-0002-1873-3064
|b 19
700 1 _ |a Fischer, Andre
|0 P:(DE-2719)2000047
|b 20
|u dzne
700 1 _ |a Nho, Kwangsik
|b 21
700 1 _ |a Initiative, Alzheimer's Disease Neuroimaging
|b 22
|e Collaboration Author
773 _ _ |a 10.1002/alz.14230
|g Vol. 20, no. 11, p. 7698 - 7714
|0 PERI:(DE-600)2201940-6
|n 11
|p 7698 - 7714
|t Alzheimer's and dementia
|v 20
|y 2024
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/272964/files/DZNE-2024-01343.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/272964/files/DZNE-2024-01343.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:272964
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2812548
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811063
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810773
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2810585
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811099
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2000047
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-25
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2023-10-25
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-25
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 0
920 1 _ |0 I:(DE-2719)1440016
|k Bioinformatics Unit (Göttingen)
|l Bioinformatics and Genome Dynamics Core (Göttingen)
|x 1
920 1 _ |0 I:(DE-2719)1410004
|k AG Sananbenesi
|l Genome Dynamics in Neurodegenerative Diseases
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1440016
980 _ _ |a I:(DE-2719)1410004
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21